These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27013651)

  • 1. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.
    Vitale C; Ahn IE; Sivina M; Ferrajoli A; Wierda WG; Estrov Z; Konoplev SN; Jain N; O'Brien S; Farooqui M; Keating MJ; Wiestner A; Burger JA
    Haematologica; 2016 Jun; 101(6):e254-8. PubMed ID: 27013651
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment.
    Suzuki T; Miyakoshi S; Nanba A; Uchiyama T; Kawamoto K; Aoki S
    J Clin Exp Hematop; 2018 Sep; 58(3):136-140. PubMed ID: 30012921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.
    Hampel PJ; Larson MC; Kabat B; Call TG; Ding W; Kenderian SS; Bowen D; Boysen J; Schwager SM; Leis JF; Chanan-Khan AA; Muchtar E; Hanson CA; Slager SL; Kay NE; Chaffee KG; Shanafelt TD; Parikh SA
    Br J Haematol; 2018 Nov; 183(3):421-427. PubMed ID: 30117139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib.
    Wanner D; Bohn JP; Rudzki J; Stockhammer G; Steurer M
    Ann Hematol; 2019 Jan; 98(1):205-207. PubMed ID: 29804266
    [No Abstract]   [Full Text] [Related]  

  • 5. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
    Hampel PJ; Call TG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Rabe KG; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
    Am J Hematol; 2020 Mar; 95(3):E57-E60. PubMed ID: 31788844
    [No Abstract]   [Full Text] [Related]  

  • 6. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
    Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
    Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.
    Gordon MJ; Sitlinger A; Salous T; Alqahtani H; Churnetski M; Rivera X; Wisniewski P; Cohen J; Patel K; Shadman M; Choi M; Hill B; Stephens D; Persky D; Brander D; Danilov AV
    Leuk Res; 2020 Feb; 89():106302. PubMed ID: 31982152
    [No Abstract]   [Full Text] [Related]  

  • 8. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
    Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
    Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.
    Ghez D; Calleja A; Protin C; Baron M; Ledoux MP; Damaj G; Dupont M; Dreyfus B; Ferrant E; Herbaux C; Laribi K; Le Calloch R; Malphettes M; Paul F; Souchet L; Truchan-Graczyk M; Delavigne K; Dartigeas C; Ysebaert L;
    Blood; 2018 Apr; 131(17):1955-1959. PubMed ID: 29437588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
    Sun C; Gao J; Couzens L; Tian X; Farooqui MZ; Eichelberger MC; Wiestner A
    JAMA Oncol; 2016 Dec; 2(12):1656-1657. PubMed ID: 27533065
    [No Abstract]   [Full Text] [Related]  

  • 11. Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
    Manda S; Dunbar N; Marx-Wood CR; Danilov AV
    Br J Haematol; 2015 Sep; 170(5):734-6. PubMed ID: 25716177
    [No Abstract]   [Full Text] [Related]  

  • 12. Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia.
    Peri AM; Rossio R; Tafuri F; Benzecry V; Grancini A; Reda G; Bandera A; Peyvandi F
    Ann Hematol; 2019 Dec; 98(12):2847-2849. PubMed ID: 31741032
    [No Abstract]   [Full Text] [Related]  

  • 13. Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia.
    Rider TG; Grace RJ; Newman JA
    Br J Haematol; 2016 Apr; 173(2):326-7. PubMed ID: 26195269
    [No Abstract]   [Full Text] [Related]  

  • 14. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.
    Rogers KA; Ruppert AS; Bingman A; Andritsos LA; Awan FT; Blum KA; Flynn JM; Jaglowski SM; Lozanski G; Maddocks KJ; Byrd JC; Woyach JA; Jones JA
    Leukemia; 2016 Feb; 30(2):346-50. PubMed ID: 26442611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ventricular arrhythmias and sudden death in patients taking ibrutinib.
    Lampson BL; Yu L; Glynn RJ; Barrientos JC; Jacobsen ED; Banerji V; Jones JA; Walewska R; Savage KJ; Michaud GF; Moslehi JJ; Brown JR
    Blood; 2017 May; 129(18):2581-2584. PubMed ID: 28223277
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
    Finnes HD; Chaffee KG; Call TG; Ding W; Kenderian SS; Bowen DA; Conte M; McCullough KB; Merten JA; Bartoo GT; Smith MD; Leis J; Chanan-Khan A; Schwager SM; Slager SL; Kay NE; Shanafelt TD; Parikh SA
    Leuk Lymphoma; 2017 Jun; 58(6):1376-1383. PubMed ID: 27820970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
    Gordon MJ; Churnetski M; Alqahtani H; Rivera X; Kittai A; Amrock SM; James S; Hoff S; Manda S; Spurgeon SE; Choi M; Cohen JB; Persky D; Danilov AV
    Cancer; 2018 Aug; 124(15):3192-3200. PubMed ID: 29797667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia--response to Rider et al.
    Danilov AV
    Br J Haematol; 2016 Apr; 173(2):327-8. PubMed ID: 26195155
    [No Abstract]   [Full Text] [Related]  

  • 19. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
    Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
    [No Abstract]   [Full Text] [Related]  

  • 20. Ibrutinib induced acute tubular injury: A case series and review of the literature.
    Manohar S; Bansal A; Wanchoo R; Sakhiya V; Lucia S; Jhaveri KD
    Am J Hematol; 2019 Sep; 94(9):E223-E225. PubMed ID: 31148235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.